Table 1.
Demographics and clinical characteristics of study cohort.
| Study participant characteristics | N = 22 |
|---|---|
| Female sex (n, %) | 9 (41%) |
| Race (n, %) | |
| Black | 1 (5%) |
| White | 13 (59%) |
| Other | 8 (36%) |
| Ethnicity (n, %) | |
| Hispanic | 8 (36%) |
| CFTR genotype (n, %) | |
| F508del homozygous | 10 (45%) |
| F508del heterozygous | 5 (23%) |
| Other | 7 (32%) |
| Comorbidities (n, %) | |
| Reflux | 21 (95%) |
| Pancreatic insufficiency | 19 (86%) |
| Asthma/reactive airway disease | 16 (73%) |
| Sinusitis | 6 (27%) |
| CF related diabetes | 4 (18%) |
| Age at first PEx (mean, SD) | 14.6 (5.0) |
| BMI at first PEx (mean, SD) | 19.5 (3.4) |
| BMI Z score at first PEx (mean, SD) (n = 19) | − 0.06 (1.02) |
| BMI percentile at first PEx (mean, SD) (n = 19) | 49.4 (29.9) |
| Best ppFEV1 6 months prior to first PEx (SD) | 81.2 (27.0) |
| Best ppFVC 6 months prior to first PEx (SD) | 92.0 (27.1) |
| Best ppFEF25-75 6 months prior to first PEx (SD) | 64.7 (37.0) |
| Disease stage at first PEx, based on best ppFEV1 6 months prior to first PEx (n, %) | |
| Early (ppFEV1 > 70%) | 14 (64%) |
| Intermediate (ppFEV1 40–70%) | 7 (32%) |
| Advanced (ppFEV1 < 40%) | 1 (4%) |
| # PEx contributing to study (mean, SD) | 2.0 (1.0) |
| Current culture results (n, %) | |
| MSSA | 6 (14%) |
| MRSA | 8 (19%) |
| Pseudomonas aeruginosa | 20 (47%) |
| Achromobacter xylosoxidans | 1 (2%) |
| Burkholderia cepacia complex* | 4 (9%) |
| Burkholderia gladioli | 3 (7%) |
| GP organism, other† | 1 (2%) |
| GN organism, other‡ | 3 (7%) |
| PK sufficient (n, %) | 12 (28%) |
| Broad antibiotic spectrum (n, %) | 18 (42%) |
| Primary beta-lactam used (n, %)‖ | |
| Ceftazidime | 16 (37%) |
| Cefepime | 9 (21%) |
| Piperacillin-tazobactam | 7 (16%) |
| Meropenem | 11 (26%) |
*B. cepacia complex = 3 B. cepacia, 1 B. multivorans.
†GP, other = Streptococcus pyogenes.
‡GN, other = Acinetobacter baumanii (n = 1), Pseudomonas putida (n = 1), Unidentified GNR (n = 1).
‖In two instances, meropenem + ceftazidime was administered for Burkholderia sp. Considered meropenem as the primary beta-lactam as the organism was resistant to ceftazidime but susceptible to meropenem or because was resistant to both and meropenem had lower MIC. In one instance, meropenem followed ceftazidime for P. aeruginosa (switched due to rash on day 9). Organism was resistant to ceftazidime but susceptible to meropenem, so used meropenem as primary for analysis. In one instance, meropenem + piperacillin/tazobactam was administered for Burkholderia sp. Considered meropenem as the primary beta-lactam as the organism was resistant to pip/tazo but susceptible to meropenem.